TL;DR
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
The FDA approved pritelivir (Hovilpri) for mucocutaneous herpes simplex virus lesions in immunocompromised patients whose infections have not responded to other treatments. In the 101-patient phase III PRIOH-1 trial, 63% of those given pritelivir had all lesions heal by day 28, compared with 34% receiving a physician-selected alternative.
The FDA approved pritelivir (Hovilpri), an oral drug, for herpes simplex virus (HSV) mucocutaneous lesions in immunocompromised patients whose infections have not responded to other treatments. The approval addresses a difficult-to-treat group with limited options when standard antiviral medicines fail.
The approval covers lesions caused by HSV infections in patients with compromised immune systems who have not responded to treatment with acyclovir, valacyclovir or famciclovir. Pritelivir is an oral helicase-primase inhibitor; the report says it works against HSV-1 and HSV-2 strains resistant to nucleoside analogue- and foscarnet-based treatments.
The FDA’s decision was based on the open-label, phase III PRIOH-1 trial, which enrolled 101 immunocompromised patients with mucocutaneous HSV infection that had not responded to prior therapy. Participants received once-daily pritelivir or an investigator-selected treatment: foscarnet, cidofovir or imiquimod.
By day 28, 63% of patients taking 100 mg of pritelivir daily had all lesions healed, meeting the trial’s primary efficacy endpoint. The corresponding result was 34% among patients receiving the selected comparison treatment. Headache was the most common adverse reaction reported among patients who received pritelivir.
A New Option After HSV Treatment Failure
The approval offers a new treatment option for immunocompromised people whose HSV lesions persist despite commonly used antiviral medicines. In people with weakened immune systems, HSV can cause lesions on areas including the lips, nostrils, eyes and genitals, and treatment-resistant infection can be especially challenging to manage.
The trial’s results provide a direct comparison with several treatments clinicians may select for these patients. The difference in the share of participants whose lesions had all healed by day 28—63% with pritelivir versus 34% with the comparator group—supports the drug’s role in this specific setting. The figures do not establish how it performs in people with HSV who are not immunocompromised or whose infections respond to standard treatment.
HSV infections are incurable, according to the source report, so this approval concerns treatment of lesions rather than eradication of the virus. The reported trial outcome measures lesion healing; it does not, by itself, establish effects on future recurrences or long-term viral control.
Products Worth Considering
Oral-B iO Series 9 Limited Rechargeable Electric Toothbrush with 7 Cleaning Modes
Oral-B iO Series 5 Rechargeable Electric Toothbrush with Travel Case, White
Oral-B iO Series 3 Rechargeable Electric Toothbrush for Adults, Black
As an affiliate, we earn on qualifying purchases.
Trial Population and Treatment Comparison
PRIOH-1 included patients with a range of conditions associated with immune suppression, including hematologic cancers or disorders, stem-cell transplants, HIV infection, autoimmune or inflammatory diseases, other cancers and solid-organ transplants. The findings therefore relate to a medically varied group, but all participants had mucocutaneous HSV infection that had not responded to specified prior treatment.
The study was open-label, meaning treatment assignments were not concealed from participants and investigators. It compared once-daily pritelivir with an investigator’s choice among three treatments, rather than with one uniform comparator. The available report describes the primary endpoint and the most common adverse reaction but does not provide detailed safety rates, additional trial outcomes or subgroup results.
“Achieving rapid lesion healing while maintaining tolerability is essential.”
— Cynthia Wat, MD, chief medical officer of Aicuris
Questions Beyond Day-28 Healing
The report does not specify the full prescribing information, including the approved dosing instructions, warnings, monitoring requirements or how clinicians should select patients. It also gives no detailed breakdown of adverse events beyond identifying headache as the most common reaction among pritelivir recipients.
It remains unclear from the available material how durable lesion healing was after day 28, whether the results differed across the varied immunocompromising conditions, or how the drug compares with each alternative individually. The trial was open-label and involved 101 patients; the report does not provide further information about study limitations or longer-term outcomes. The approval applies to the population described, not to all people with HSV.
Prescribing Details and Longer-Term Evidence
Clinicians and patients will need to consult the FDA-approved prescribing information for the drug’s authorized use, dosing, safety guidance and precautions. The source report does not give a timeline for distribution or additional regulatory or research milestones.
Further evidence could clarify how well lesion healing is maintained, what adverse reactions occur beyond headache, and whether outcomes vary among patients with different causes of immunosuppression. For now, the confirmed approval and reported trial results concern treatment-refractory mucocutaneous HSV lesions in immunocompromised patients.
Key Questions
Who is pritelivir approved to treat?
The FDA approved it for mucocutaneous lesions caused by HSV in immunocompromised patients whose infections have not responded to other treatments. The report identifies prior treatment with acyclovir, valacyclovir or famciclovir.
What did the phase III trial find?
In PRIOH-1, 63% of patients taking 100 mg of pritelivir once daily had all lesions healed by day 28, compared with 34% of patients given an investigator-selected treatment: foscarnet, cidofovir or imiquimod.
Does pritelivir cure herpes?
No cure is established by the reported approval or trial findings. The approval is for treating HSV-related lesions; HSV infections are described in the source report as incurable.
What side effect was reported most often?
Headache was the most common adverse reaction reported among patients who received pritelivir. The source material does not provide a full list of side effects or their rates.
Source: rss
